



# DT05 Rec'd PCT/PT0 7 5 6CT 2002

ATTORNEY DOCKET NO. 14014.0322U2
PATENT

# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of	)	
Confirmation No. Unassigned	)	
Libutti <i>et al</i> .	)	Group Art Unit: Unassigned
Serial No. 10/031,008	)	Examiner: Unassigned
Filed: November 7, 2001	)	
For: "METHODS FOR TREATING TUMORS USING ANTIANGIOGENIC COMPOUNDS"	) ) )	

### INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents Washington, D.C. 20231

NEEDLE & ROSENBERG, P.C. The Candler Building 127 Peachtree Street, N.E. Atlanta, Georgia 30303-1811

October 9, 2002

Sir:

Pursuant to the requirements of 37 C.F.R. § 1.56, submitted herewith on the accompanying Form PTO -1449 is a listing of documents known to the applicants and/or their attorneys. A copy of each of these documents is enclosed.

Consideration of the cited documents and making the same of record in the prosecution of the above-referenced application are respectfully requested.

# ATTORNEY DOCKET NO. 14014.0322U2 SERIAL NO. 10/031,008

No fee is believed due; however, the Commissioner is hereby authorized to charge any fees which may be required, or credit any overpayment to Deposit Account No. 14-0629.

Respectfully submitted,

NEEDLE & ROSENBERG, P.C.

Gwendolyn D. Spratt
Registration No. 36,016

NEEDLE & ROSENBERG, P.C. The Candler Building 127 Peachtree Street, N.E. Atlanta, Georgia 30303-1811 404/688-0770

#### Certificate of Mailing Under 37 C.F.R. § 1.8

I hereby certify that this correspondence and any items indicated as attached or included are being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231, on the date indicated below.

Gwendolyn D. Spratt

Date



Form PTO-1449 U.S. DEPARTMENT OF COMMERCE (Rev. 7-80) PATENT AND TRADEMARK OFFICE **ATTORNEY DOCKET NO.:** 14014.0322U2

**SERIAL NO.** 10/031,008

APPLICANT: Libutti et al.

LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)

FILING DATE: November 7, 2001 GROUP: Unassigned

(Use several sheets if necessary)		FILING DATE: November 7, 2001	GROUP: U	GROUP: Unassigned			
	U.S. PATENT DOCUMENTS						
EXAMINER INITIALS	·	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	<u> </u>		F(	OREIGN PATENT DOCUMENTS		_	
	A1	WO 98/49321A	11/05/98	Hong et al.			
	A2	WO 98/48834A	11/05/98	Sinai School of Medicine			
	A3	WO 97/16169A	05/09/97	Chiron Corp.			
	A4	WO 97/34586A	09/25/97	Cytotherapeutics, Inc.			
		OTHE	R PRIOR ART (I	Including Author, Title, Date, Pertinent	Pages, Etc.)		
	A5	Bramson et al. "Direct Intratumoral Injection of an Adenovirus Expressing Interleukin-12 Induces Regression and Long-Lasting Immunity That Is Associated With Highly Localized Expression of Interleukin-12" <i>Hum. Gene Ther.</i> 7:1995-2002 (October 20, 1996)					
	A6	Blezinger et al. "Systemic inhibition of tumor growth and tumor metastases by intramuscular administration of the endostatin gene" 17(4):343-348 (April 1999)					
	A7	Cao "Endogenous Angiogenesis Inhibitors: Angiostatin, Endostatin, and other Proteolytic Fragments" <i>Prog. Mol. Subcell Biol.</i> 20:161-176 (1998)					
	A8	Chen et al. "Liposomes Complexed to Plasmids Encoding Angiostatin and Endostatin Inhibit Breast Cancer in Nude Mice" Cancer Res. 59:3308-3312 (July 1999)					
	A9	Crystal. "The body as a manufacturer of endostatin" Nat. Biotech. 17:336-337 (April 1999)					
	A10	Ferry et al. "Liver-Directed Gene Transfer Vectors" Hum. Gene. Ther. 9:1975-1981 (September 1998)					
	A11	Folkman "Angiogenesis in cancer, vascular, rheumatoid and other diseases" Nature Med. 1(1):27-30 (1995)					
	A12	Folkman "J Antiangiogenic gene therapy" Pro. Natl. 95:9064-9066 (August 1998)					
	A13	Hogaboam et al. "Macrophage inflammatory protein-2 gene therapy attenuates adenovirus- and acetaminophen-mediated hepatic injury" Gene Ther. 6:573-584 (1999)					
	A14	Katayose et al. "Cytotoxic Effects of Adenovirus-Mediated Wild Type p53 Protein Expression in Normal and Tumor Mammary Epithelial cells" Clin. Cancer Res. 1:889-898 (August 1995)					
	A15	Katayose et al. "Effects of a Recombinant Adenovirus Expressing WAF1/Cipl on Cell Growth, Cell Cycle, and Apoptosis" Cell Growth Differ 6:1207-1212 (October 1995)					
	A16	Kong et al. "Gene Therapy Strategies for Tumor Antiangiogenesis" J. Natl. Cancer Inst 90(4):273-286 (1998)					
	A17	Lin et al. "Antiangiogenic gene therapy targeting the endothelium-specific receptor tyrosine kinase Tie2" <i>Pro Natl Acad Sci</i> 95:8829-8834 (July 1998)					
	A18	O'Reilly et al. "Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth" Cell 88:277-285 (January 1997)					
	A19	Persson et al. "Multiple mRNA species for the precursor to an adenovirus-encoded glycoprotein: Identification and structure of the signal sequence" <i>Proc. Natl.</i> 77(11):6349-6353 (November 1980).					
	A20	Pike et al. "Vasostatin a Calreticulin Fragment, Inhibits Angiogenesis and Suppresses Tumor Growth" <i>J. Exp. Med.</i> 188(12):2349-2356 (December 21, 1998)					

OCT 1.5 20	البر - 20		Page 2 of 2			
& MADEM	21	Ramchandran et al. "Antiangiogenic Biochem. Biophys. Res. Comm. 255	Activity of Restin, NC10 Domain of Human Collagen XV: Comparison to Endostatin" (3):735-739 (February 24, 1999)			
	A22	Ramchandran et al. "Cloning, expression of a novel anti-angiogenic protein: Restatin" <i>Proc. Am. Assoc. Cancer Res.</i> 40:620 (March 1999)				
	A23	Sauter et al. "Adenovirus-mediated gene transfer of endostatin <i>in vivo</i> results in high level of transgene expression and inhibition of tumor growth and metastases" <i>Proc Natl. Sci.</i> USA 97(9):4802-4807 (April 25, 2000)				
	A24	Schwarz et al. "EMAP II: A modulator or neovascularization in the developing lung" Am. J. Physiol. 20(2):L365-375 (February, 1999)				
	A25	Shuttleworth. "Type VIII Collagen" Int. J. Biochem. Cell Biol. 29(10):1145-1148 (October 1997)				
	A26	Tanaka et al. "Viral Vector-targeted Antiangiogenic Gene Therapy Utilizing an Angiostatin Complementary DNA" Cancer Res. 58(15):3362-3369 (August 1, 1998)				
	A27	Tanaka et al. "Viral vector-mediated transduction of a modified platelet factor 4 cDNA inhibits angiogenesis and tumor growth" Nat. Med. 3(4):437-442 (1997)				
	A28	Tomko et al. "HCAR and MCAR: The human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses" <i>Proc. Natl. Acad. Sci.</i> 94:3352-3356 (April 1997)				
EXAMINER:			DATE CONSIDERED:			
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.						